Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIEOP-BFM ALL 2017
NCT03643276Phase 3Recruiting
- Start
- Jul 2018
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, scFv Fragments, Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of blinatumomab and bortezomib in acute lymphoblastic leukemia (ALL) (10 arms). Primary endpoints: Event-free survival at 120 months and Disease-free survival at 120 months. Started Jul 2018; status: recruiting.
02
Drugs
blinatumomabbortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03643276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643276.